AB1131 PATIENT ACCEPTABLE SYMPTOMS STATE IN PSORIATIC ARTHRITIS: DOES IT DIFFER BETWEEN SEXES?
Authors: S. Scriffignano, F. M. Perrotta, M. Fatica, P. Triggianese, P. Conigliaro, M. Ferraioli, M. S. Chimenti, E. Lubrano
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patient Acceptable Symptoms State (PASS) is a dichotomous and feasible tool recently validated for Psoriatic Arthritis (PsA). It assesses if the patient accepts her/his disease status by using a simple question: "Think about all the ways your PsA has affected you during the last 48 hours. If you were to remain in the next few months as you were during the last 48 hours, would this be acceptable to you?". A negative answer ("no") denotes a disease status not acceptable for the patient. Due to the recent introduction of PASS in PsA, there are not data about its difference between sexes. <h3>Objectives</h3> To assess PASS differences in PsA based on sexes, characterizing the factors associated with an unacceptable disease state (PASS "no"). <h3>Methods</h3> This is a cross sectional study. Patients were consecutively enrolled from January 2022 to December 2022, in two outpatient clinics devoted to PsA. All enrolled patients were adult and had a PsA diagnosis (for at least six months). We assessed PASS and its difference between sexes (χ<sup>2</sup> test). Moreover, we performed two logistic regression models to assess which factors were associated with PASS "no", in both sexes. <h3>Results</h3> Two-hundred and forty-five patients were enrolled. Female less accepted their disease status, compared with male patients, PASS "no" was 49.1% vs 23.5%, (p&lt;0.001) (Table1). The factor associated with a higher probability to have an unacceptable symptoms state was a higher disease activity (Table 2), both for male and female. In particular, for male patients, when DAPSA increases of 1 point, the probability to have a state of PASS "no" increases of 31% (OR 1.31, CI 95% 1.16-1.47), independently by age, disease durations, BMI and BSA. The same result was confirmed for female patients, but with a stronger association: when DAPSA increases of 1 points the probability to have a state of PASS "no" increase of 101% (OR 2.01, CI 95% 1.45-2.77), independently by age, disease durations, BMI, BSA and fibromyalgia. Moreover, fibromyalgia in female patients was not associated with PASS "no". <h3>Conclusion</h3> Female patients perceive their disease acceptable less than male. A higher disease activity (assessed by DAPSA), in particular for female patients, is the main factor to predict a state of non-acceptance of the disease. <h3>Reference</h3> [1]Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Cañete JD, Perrotta FM. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020 Mar;6(1):e001170. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> silvia scriffignano: None declared, Fabio Massimo Perrotta Speakers bureau: Lilly, Novartis, AbbVie, Mauro Fatica: None declared, Paola Triggianese: None declared, Paola Conigliaro: None declared, Mario Ferraioli: None declared, Maria Sole Chimenti: None declared, Ennio Lubrano Speakers bureau: Lilly, Pfizer, AbbVie, Novartis, Janssen, Amgen, Consultant of: Lilly, Pfizer, AbbVie, Novartis, Janssen, Amgen.